BioCapital
Filter News
Found 43,545 articles
-
Danaher Reports First Quarter 2024 Results
4/23/2024
Danaher Corporation announced results for the quarter ended March 29, 2024. All results in this release reflect only continuing operations unless otherwise noted.
-
Adial Pharmaceuticals Granted Key Patent from the United States Patent and Trademark Office
4/22/2024
Adial Pharmaceuticals, Inc. today announced patent number 11957664 was issued April 16, 2024 by the United States Patent and Trademark Office.
-
Theriva™ Biologics to Present Preclinical Data Supporting the Potential Synergy of VCN-01 and First-Line Pancreatic Cancer Chemotherapy Regimens at the American Society for Cell and Gene Therapy 27th Annual Meeting
4/22/2024
Theriva™ Biologics announced the presentation of preclinical data demonstrating enhanced anti-tumor effects in human pancreatic cancer xenograft-bearing mice treated with lead product candidate VCN-01 and liposomal irinotecan.
-
Owens & Minor Announces First Quarter 2024 Earnings Release Date and Conference Call
4/22/2024
Owens & Minor, Inc. plans to release financial results for the first quarter of 2024 on Friday, May 3, 2024, before trading begins on the New York Stock Exchange.
-
Salubris Biotherapeutics Announces $35 Million in Financing and Provides Pipeline Progress Update
4/22/2024
Salubris Biotherapeutics, Inc. today announced a new capital infusion of $35 million to fund continued research and development of clinical and pre-clinical programs.
-
Emergent BioSolutions to Release First Quarter 2024 Financial Results & Conduct Conference Call on May 1, 2024
4/22/2024
Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Wednesday, May 1, 2024, at 5:00 pm eastern time to discuss the financial results for the first quarter 2024, key business updates, revenue guidance for the second quarter of 2024, and financial outlook for full year 2024. Conference Call Information Participants can access the conference call live via webcast.
-
Cartesian Therapeutics to Present at the ASGCT 27th Annual Meeting
4/22/2024
Cartesian Therapeutics, Inc. (NASDAQ:RNAC) (the “Company”) today announced that recently reported twelve-month follow-up data from its Phase 2a trial of Descartes-08 in patients with generalized myasthenia gravis will be featured during an oral presentation at the upcoming American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting being held May 7-11, 2024.
-
FDA Roundup: April 19, 2024
4/19/2024
The U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency.
-
Vaccinologists Keith Klugman and Shabir Madhi Awarded Sabin’s Prestigious Gold Medal; Infectious Diseases Epidemiologist Nicole Basta Receives Rising Star Award
4/19/2024
The Sabin Vaccine Institute yesterday presented the Albert B. Sabin Gold Medal to physician-researchers Keith Paul Klugman and Shabir Ahmed Madhi, and its Rising Star award to infectious diseases epidemiologist Nicole Elaine Basta at a ceremony in the National Academy of Sciences building in Washington D.C.
-
YS Biopharma Announces Unaudited Financial Results for the First Nine Months of Fiscal Year 2024
4/19/2024
YS Biopharma Co., Ltd. today announced its unaudited consolidated financial results for the first nine months of the fiscal year ended March 31, 2024.
-
YS Biopharma Granted Phase I Clinical Trial License of Therapeutic Chronic Hepatitis B Virus Vaccine
4/18/2024
YS Biopharma Co., Ltd. today announced that its YS-HBV-002 immunotherapeutic vaccine, designed to treat patients suffering from chronic hepatitis B virus ("HBV") infection, has been granted clinical trial approval by the Philippine Food and Drug Administration ("PFDA").
-
Novel cell therapy treatments offer promise to immune-compromised children
4/18/2024
In a first-of-its-kind clinical trial, researchers found that intravenous therapies made from virus-specific T-cells can effectively treat immunocompromised pediatric patients, far surpassing the current standard of care, according to new research published in Nature Communications.
-
NIH researchers develop AI tool with potential to more precisely match cancer drugs to patients
4/18/2024
In a proof-of-concept study, researchers at the National Institutes of Health have developed an artificial intelligence tool that uses data from individual cells inside tumors to predict whether a person's cancer will respond to a specific drug.
-
Castellum, Inc. Announces New Strategic Alliance
4/18/2024
Castellum, Inc. announces a new strategic alliance between its subsidiary Specialty Systems, Inc. (“SSI”) (www.specialtysystems.com ) and Epic Systems, Inc. (“Epic”) (www.epicinfotech.com ).
-
Vanda Pharmaceuticals Adopts Limited Duration Stockholder Rights Plan
4/17/2024
Vanda Pharmaceuticals Inc. announced that its Board of Directors has adopted a limited duration stockholder rights plan to protect stockholder interests and maximize value for all stockholders.
-
Vanda Pharmaceuticals Confirms Rejection of Unsolicited Takeover Proposals from Future Pak
4/17/2024
Vanda Pharmaceuticals Inc. ("Vanda" or the "Company") (Nasdaq: VNDA) today confirmed that, since March 2024 , it received several unsolicited proposals from Future Pak, LLC ("Future Pak"), to acquire all of the outstanding shares of Vanda (the "Conditional Proposals"). The most recent proposal from April 1 offered $7.25 - $7.75 per share, subject to certain terms and conditions.
-
Pantheon Vision Announces Two Successful Pre-Submission Meetings With the FDA
4/17/2024
Pantheon Vision announced today the completion of two successful and productive Pre-Submission meetings with the U.S. Food and Drug Administration (FDA).
-
Lupus Accelerating Breakthroughs Consortium Announces Expanded Partnership with U.S. FDA at First Anniversary Meeting
4/16/2024
The Lupus Research Alliance (LRA), founder and administrator of the Lupus Accelerating Breakthroughs Consortium (Lupus ABC), announced today at the Consortium's first anniversary meeting an expanded partnership with the U.S. Food and Drug Administration (FDA) with the inclusion of the Center for Biologics Evaluation and Research (CBER).
-
IGC-AD1’s Interim Phase 2 Data Show a Reduction in Alzheimer’s Agitation at Week Two
4/16/2024
IGC Pharma, Inc. (“IGC Pharma,” “IGC,” or the “Company”) (NYSE American: IGC) today announced that interim data from its Phase 2 clinical trial demonstrates a clinically significant reduction, approaching statistical significance, in agitation in Alzheimer’s at week two compared to placebo.
-
IMFINZI® (durvalumab) plus chemotherapy doubled overall survival rate at three years for patients with advanced biliary tract cancer in TOPAZ-1 Phase III trial
4/16/2024
Updated exploratory results from the TOPAZ-1 Phase III trial showed AstraZeneca’s IMFINZI ® (durvalumab) in combination with standard-of-care chemotherapy demonstrated a clinically meaningful long-term overall survival (OS) benefit at three years for patients with advanced biliary tract cancer (BTC).